Acetic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Acetic Acid: From Haemodialysis Acid Concentrate Component to Post-Bacterial Disorder
One-Sentence Summary
Acetic acid is registered in South Africa as a component of haemodialysis acid concentrate products, and the records give no approved indication text. The TxGNN model predicts it may be useful for post-bacterial disorder, a very broad, non-specific term. The evidence is thin: 18 matched clinical trials, none of which tests acetic acid for this condition, and 0 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration records (the registered products are haemodialysis acid concentrates) |
| Predicted New Indication | Post-bacterial disorder |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only; the source data assigns L4, but no matched study tests acetic acid) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, acetic acid is used in South Africa as an ingredient of haemodialysis concentrates. No original therapeutic indication is documented, so the link between its established use and the predicted indication cannot be validated.
Topical acetic acid does have a plausible antibacterial rationale: local acidification and disruption of biofilm. That would fit the antimicrobial and irrigation studies among the matched trials. However, “post-bacterial disorder” is an umbrella term rather than a defined disease. The high model score (99.98%) therefore says little about a specific, testable clinical question.
Clinical Trial Evidence
Eighteen trials matched this prediction. None studies acetic acid as a treatment for a defined post-bacterial condition. The most relevant ones are listed below, and most are context only.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03212729 | N/A | Completed | 10 | Antimicrobial photodynamic therapy as an add-on to root canal treatment for apical periodontitis; acetic acid is not the intervention |
| NCT04824261 | N/A | Unknown | 100 | 4% boric acid vs clotrimazole in otomycosis (fungal ear infection); acetic acid not tested |
| NCT04036318 | N/A | Completed | 3,022 | Presumptive periodic treatment of STIs in high-risk groups in Tanzania; not an acetic acid study |
| NCT04120259 | N/A | Completed | 126 | Apple cider vinegar (contains acetic acid) plus metformin in type 2 diabetes; a dietary product in an unrelated disease |
| NCT07048028 | N/A | Recruiting | 90 | Chitosan vs sodium hypochlorite combinations as root canal irrigants; antibacterial comparison, acetic acid not studied |
| NCT03619161 | N/A | Completed | 58 | Effect of cleaning the bathroom environment on eczema severity (bleach bath context) |
| NCT05710094 | Phase 1 | Completed | 28 | Safety and tolerability of a topical biofilm eradicator (SoftOx) in chronic leg wounds |
| NCT04657757 | N/A | Completed | 16 | Ex vivo bacterial adhesion and bactericidal effect on implant restoration materials |
| NCT06135116 | N/A | Completed | 60 | Regulatory T cells and interleukins in periodontal disease progression |
| NCT05275647 | Phase 2 | Unknown | 75 | Low-energy shock wave plus botulinum toxin A in refractory interstitial cystitis |
No SANCTR or PACTR registrations were identified.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. A39/34/0163 | Sabax Low Magnesium Acid Diasol (1000 ml) | Solution |
| Reg. No. 29/34/0328 | Haemocarb acid concentrate 5 L AFM7204 | Infusion |
| Reg. No. A39/34/0168 | Sabax Standard Acute Acid Diasol | Solution |
| SECTION 21 | Haemodialysis Concentrate | Solution |
The registration records contain no approved indication text. The last entry is a Section 21 authorisation, not a full registration. All four products are dialysis-related concentrates, not products for treating bacterial or post-bacterial conditions.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but “post-bacterial disorder” is too non-specific to test. None of the 18 matched trials evaluates acetic acid for it, there is no supporting literature, and the mechanism and original indication are undocumented. The other nine predicted indications are also Hold. Of these, tinea corporis has the most credible topical antifungal rationale, but it still has no trials or literature.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data, for example from DrugBank
- A specific, clinically defined condition to replace “post-bacterial disorder”
- Route and formulation compatibility: the registered products are dialysis concentrates, not topical or other therapeutic formulations
- Any trial that directly tests acetic acid, ideally for a defined condition
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.